drugset / Trial / NCT02757079

Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders

NCT02757079

Phase 3 Completed 99 enrolled Nobelpharma
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy on sleep latency with electronic sleep diaries and the safety of NPC-15.

Timeline

Start
2016-06-21
Primary completion
2018-07
Completion
2018-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 1 mg Oral
Subject Melatonin Small molecule 2 mg Oral
Subject Melatonin Small molecule 4 mg Oral